Literature DB >> 20033412

Clarithromycin in adult-onset Still's disease: a study of 6 cases.

Gianantonio Saviola1, Maurizio Benucci, Lul Abdi-Ali, Paola Baiardi, Mariangela Manfredi, Mariarosaria Bucci, Giuseppe Cirino.   

Abstract

Adult-onset Still's disease (AOSD) is a rare rheumatological condition characterized by an acute systemic involvement. There are no treatment guidelines. Glucocorticoids (GC), methotrexate (MTX), cyclosporin A and biologic agents have been successfully used, often in association. We treated six cases of AOSD with clarithromycin (CM) in combination with low-mild dose of GC and MTX. Four of them were not responsive to high-dose GC added to DMARDs, while two of them were treated with low-mild dose of GC added to CM from the beginning. CM, 500 mg b.i.d., was added to a mild-low dose of GC and to MTX. The dose of the drugs was reduced (and stopped where possible) following clinical and laboratory parameters. ACR criteria were used to assess clinical improvement. At 6 months 5 patients reached ACR 70% and could stop any therapy in 6-18 months; 1 continued chronic therapy with low-dose GC added to CM and MTX to maintain ACR 50%. CM can be a useful drug for the treatment of AOSD, even in patients not responsive to high-dose GC and DMARDs. No definitive conclusion can be drawn based on the present study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20033412     DOI: 10.1007/s00296-009-1277-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  20 in total

1.  Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.

Authors:  B Fautrel; J Sibilia; X Mariette; B Combe
Journal:  Ann Rheum Dis       Date:  2004-06-07       Impact factor: 19.103

2.  Clarithromycin in adult-onset Still's disease. Case report with a 1-year follow-up.

Authors:  G Saviola; L Abdi Ali; S Shams Eddin; C Davoli; M Taglietti
Journal:  Clin Exp Rheumatol       Date:  2004 May-Jun       Impact factor: 4.473

3.  Preliminary criteria for classification of adult Still's disease.

Authors:  M Yamaguchi; A Ohta; T Tsunematsu; R Kasukawa; Y Mizushima; H Kashiwagi; S Kashiwazaki; K Tanimoto; Y Matsumoto; T Ota
Journal:  J Rheumatol       Date:  1992-03       Impact factor: 4.666

Review 4.  Pathogenesis and management of adult-onset Still's disease.

Authors:  Petros Efthimiou; Sharon Georgy
Journal:  Semin Arthritis Rheum       Date:  2006-09-01       Impact factor: 5.532

5.  Comments on: Effects of clarithromycin in patients with active rheumatoid arthritis.

Authors:  Gianantonio Saviola; Maurizio Benucci; Giuseppe Cirino
Journal:  Curr Med Res Opin       Date:  2007-11       Impact factor: 2.580

6.  The anti-inflammatory activity of clarithromycin inhibits TNFalpha production and prolongs survival following lipopolysaccharide administration in mice.

Authors:  Vanesa Ivetić Tkalcević; Berislav Bosnjak; Ivanka Pasalić; Boska Hrvacić; Kristina Situm; Miroslava Dominis Kramarić; Ines Glojnarić; Vesna Eraković Haber
Journal:  Int J Antimicrob Agents       Date:  2008-06-20       Impact factor: 5.283

7.  Open-label study of clarithromycin in patients with undifferentiated connective tissue disease.

Authors:  Roland W Moskowitz; Mary Lesko; Michele Hooper
Journal:  Semin Arthritis Rheum       Date:  2006-10       Impact factor: 5.532

8.  Anti-inflammatory activity of macrolide antibiotics.

Authors:  A Ianaro; A Ialenti; P Maffia; L Sautebin; L Rombolà; R Carnuccio; T Iuvone; F D'Acquisto; M Di Rosa
Journal:  J Pharmacol Exp Ther       Date:  2000-01       Impact factor: 4.030

9.  Cyclosporin A in the treatment of adult onset Still's disease.

Authors:  A Marchesoni; G P Ceravolo; N Battafarano; A Rossetti; S Tosi; F Fantini
Journal:  J Rheumatol       Date:  1997-08       Impact factor: 4.666

10.  Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease.

Authors:  B Fautrel; C Borget; S Rozenberg; O Meyer; X Le Loët; C Masson; A C Koeger; M F Kahn; P Bourgeois
Journal:  J Rheumatol       Date:  1999-02       Impact factor: 4.666

View more
  4 in total

1.  Clarithromycin in rheumatoid arthritis: the addition to methotrexate and low-dose methylprednisolone induces a significant additive value--a 24-month single-blind pilot study.

Authors:  Gianantonio Saviola; Lul Abdi-Ali; Lorella Campostrini; Silvano Sacco; Paola Baiardi; Mariangela Manfredi; Maurizio Benucci; Mariarosaria Bucci; Giuseppe Cirino
Journal:  Rheumatol Int       Date:  2013-07-18       Impact factor: 2.631

2.  Clinical characteristics and follow-up analysis of adult-onset Still's disease complicated by hemophagocytic lymphohistiocytosis.

Authors:  Yun Zhang; Yingyun Yang; Yujia Bai; Dan Yang; Yangyang Xiong; Xuejun Zeng
Journal:  Clin Rheumatol       Date:  2016-01-26       Impact factor: 2.980

Review 3.  Macrolides in chronic inflammatory skin disorders.

Authors:  Abdullateef A Alzolibani; Khaled Zedan
Journal:  Mediators Inflamm       Date:  2012-05-17       Impact factor: 4.711

Review 4.  Anti-inflammatory and Immunomodulatory Effects of Antibiotics and Their Use in Dermatology.

Authors:  Swetalina Pradhan; Bhushan Madke; Poonam Kabra; Adarsh Lata Singh
Journal:  Indian J Dermatol       Date:  2016 Sep-Oct       Impact factor: 1.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.